In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin - Emerging resistance

被引:88
作者
Kunimoto, DY [1 ]
Sharma, S [1 ]
Garg, P [1 ]
Rao, GN [1 ]
机构
[1] LV Prasad Eye Inst, Hyderabad 500034, Andhra Pradesh, India
关键词
D O I
10.1016/S0161-6420(99)90008-8
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To examine in vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Design: Retrospective review. Participants: The authors examined in vitro susceptibility of 1558 corneal isolates from 1303 patients with culture-proven bacterial keratitis seen at the LV Prasad Eye Institute in Hyderabad, India, during the 6-year period between March 1, 1991, and June 30, 1997, Results: Of 1558 corneal isolates, 478 (30.7%) were not sensitive to ciprofloxacin. Among the isolates, 355 (32.5%) of the 1091 gram-positive cocci were not sensitive to ciprofloxacin, and 2 (10%) of the 20 gram-positive bacilli, 22 (13.3%) of the 165 gram-negative organisms, and 99 (35.1%) of the 282 Actinomycetes and related organisms were not sensitive to ciprofloxacin. Results from chi-square for trends analysis showed a trend of significantly increasing ciprofloxacin insensitivity in bacteria between 1992 and 1997 (P = 0.011). Conclusion: This is the first report of significantly increasing ciprofloxacin insensitivity among corneal pathogens. Although the lowered cost and convenience of dispensing a single, commercially available antibiotic such as ciprofloxacin in the initial treatment of bacterial keratitis is desirable, the emergence of ciprofloxacin resistance is a significant finding in this series, and the clinician should proceed with caution in the initial empiric treatment of bacterial keratitis with ciprofloxacin.
引用
收藏
页码:80 / 85
页数:6
相关论文
共 18 条
[1]  
*ALC LAB INC, 1990, 19992 FOOD DRUG ADM
[2]   AN INVITRO STUDY OF THE POTENCY AND STABILITY OF FORTIFIED OPHTHALMIC ANTIBIOTIC PREPARATIONS [J].
BOWE, BE ;
SNYDER, JW ;
EIFERMAN, RA .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1991, 111 (06) :686-689
[3]   Fluoroquinolones in the treatment of bacterial keratitis [J].
Bower, KS ;
Kowalski, RP ;
Gordon, YJ .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1996, 121 (06) :712-715
[4]  
COKINGTIN C D, 1991, American Journal of Ophthalmology, V112, p25S
[5]   Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers [J].
Hyndiuk, RA ;
Eiferman, RA ;
Caldwell, DR ;
Rosenwasser, GO ;
Santos, CI ;
Katz, HR ;
Badrinath, SS ;
Reddy, MK ;
Adenis, JP ;
Klauss, V ;
COhen, E ;
MarechalCourtois, C ;
Murta, J ;
Darrell, RW ;
Denis, P ;
Heidemann, DH ;
Insler, MS ;
John, T ;
Klauss, V ;
Lass, JH ;
Limberg, MB ;
McCulley, JP ;
Rosenwasser, GOD ;
Rowsey, JJ ;
Santos, C ;
Sher, N ;
Ullman, S ;
Verin, P ;
Wilhelmus, KR ;
Wills, R ;
Wolf, TC .
OPHTHALMOLOGY, 1996, 103 (11) :1854-1862
[6]   MECHANISM OF CIPROFLOXACIN RESISTANCE IN PSEUDOMONAS-AERUGINOSA [J].
KAATZ, GW ;
SEO, SM .
JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (03) :537-541
[7]  
Knauf HP, 1996, CORNEA, V15, P66
[8]  
LEIBOWITZ H M, 1991, American Journal of Ophthalmology, V112, p34S
[9]   CIPROFLOXACIN-RESISTANT BACTERIAL KERATITIS [J].
MAFFETT, M ;
ODAY, DM .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1993, 115 (04) :545-546
[10]  
McLeod SD, 1996, OPHTHALMOLOGY, V103, P479